Cyclic vomiting syndrome is a recurrent condition characterized by episodes of severe vomiting, often leading to dehydration and distress. The CVS market is gaining attention due to rising awareness and diagnosis rates, alongside a growing understanding of its underlying causes, such as mitochondrial disorders and gastrointestinal dysmotility. Recent developments in the market include advancements in treatment options, such as preventive medications like amitriptyline and antiemetics, which aim to reduce the frequency and severity of episodes. Moreover, increased research funding and initiatives for better management strategies are driving growth. The introduction of new diagnostic tools, such as genetic testing, is expected to enhance patient identification and treatment efficacy. As healthcare providers focus on personalized care approaches, the CVS market is poised for expansion, with a projected increase in demand for innovative therapies and supportive care services.
